ImmuPharma (LON:IMM) Shares Up 12.5% – Time to Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price rose 12.5% during trading on Friday . The company traded as high as GBX 5.80 ($0.07) and last traded at GBX 5.50 ($0.07). Approximately 19,527,068 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 25,520,734 shares. The stock had previously closed at GBX 4.89 ($0.06).

ImmuPharma Price Performance

The company’s 50 day simple moving average is GBX 2.06 and its two-hundred day simple moving average is GBX 1.83. The stock has a market capitalization of £22.15 million, a P/E ratio of -532.00 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.